Telectronics Encor lead fractures prompt exit from atrial lead market.
This article was originally published in The Gray Sheet
Executive SummaryTELECTRONICS PLANS TO RE-ENTER ATRIAL PACER LEAD MARKET with redesigned passive and active leads following the devices' clearance by FDA, the company says. The new leads, which have not yet been submitted to FDA for review, are intended to replace the Encor and Accufix J-shaped leads. Cases of fracture have been reported for both devices, and they have been withdrawn from the market. The company currently is distributing substitute active and passive fixation atrial leads as replacements to the J-shape leads through an OEM manufacturer.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.